Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 5, 2017, Pages

  Mochtar, Monique H ^a   Danhof, Nora A ^a   Ayeleke, Reuben Olugbenga ^b   Van der Veen, Fulco ^a   van Wely, Madelon ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; FOLLITROPIN; LUTEINIZING HORMONE; RECOMBINANT PROTEIN;

BIRTH RATE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IN VITRO FERTILIZATION; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MONOTHERAPY; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; FEMALE; META ANALYSIS; PREGNANCY; PROCEDURES;

ABORTION, SPONTANEOUS; DRUG THERAPY, COMBINATION; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; LIVE BIRTH; LUTEINIZING HORMONE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 85019896311     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005070.pub3     Document Type: Review

References (75)

1. Abdelmassih V, Salgueiro R, Abdelmassih C, Carizza C. Less miscarriage rate using LH (rLH) in GnRH agonists long protocols. Twenty-Second Annual Meeting of the European Society of Human Reproduction and Embryology; 2006 June 18-21. Prague: ESHRE, 2006. 2976920
2. Allegra A, Pane A, Marino A, Scaglione P, Ruvolo G, Volpes A. Is rLH useful in the treatment of infertile poor prognosis patients undergoing IVF cycles? A preliminary report of a controlled trial. Abstracts of the 27th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2011 July 3-6; Stockholm. 2011:i298-9. 2976922
3. Balasch J, Creus M, Fabregues F, Civico S, Carmona F, Puerto B, et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian hyperstimulation in pituitary-suppressed women undergoing assisted reproduction. Journal of Assisted Reproductive Genetics 2001;18(5):250-6. 2976924
4. Barrenetxea G, Agirregoika JA, Jimenez MR, Lopez de Larruzea A, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomised controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertility and Sterility 2008;89(3):546-53. 2976926
5. Berkkanoglu M, Isikoglu M, Aydin D, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertilility and Sterility 2007;88(3):665-9. 2976928
6. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: An age-adjusted analysis. Fertility and Sterility 2011;95(3):1031-6. 2976930
7. Caserta D, Lisi F, Marci R, Ciardo F, Fazi A, Lisi R, et al. Does supplementation with recombinant luteinizing hormone prevent ovarian hyperstimulation syndrome in down regulated patients undergoing recombinant follicle stimulating hormone multiple follicular stimulation for IVF/ET and reduces cancellation rate for high risk of hyperstimulation?. Gynecological Endocrinology 2011;27:862-6. 2976932
8. Demirol A, Gurgan T, Girgin B. Supplementation of rec-LH for poor responder patients. Abstracts of the 21st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2005 June 19-22; Copenhagen. 2005:i74. 2976934
9. De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Human Reproduction 2005;20(2):390-6. 2976936
10. Dravid RM, Chimote BN, Chimote AN, Chimote NN, Chimote NM. Supplementation of recombinant LH to poor responders in mid-follicular phase along with recombinant FSH results in better blastocyst formation and implantation rate in antagonist IVF cycles. 31st European Society of Human Reproduction and Embryology (ESHRE); 2015 June 14-17; Lisbon. 2015:165. 5656469
11. Evangelio PM, Buendicho IE, Yeste AM, Gustem MRB, Egea IB, Hernandez NC. Randomized prospective study on the effect of the addition of the effect of the addition of business cycles exogenous LH IVF/ICSI GnRH antagonist predictors in patients with low response. Revista Iberoamericana de Fertilidad y Reproduccion Humana 2011;28(3):3. 2976938
12. Fabregues F, Iraola A, Casals G, Creus M, Carmona F, Balasch J. Evaluation of two doses of recombinant human luteinizing hormone supplementation in down-regulated women of advanced reproductive age undergoing follicular stimulation for IVF: a randomized clinical study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2011;158:56-61. 2976940
13. Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertility and Sterility 2006;85:925-31. 2976942
14. Fernández Ramírez MJ, Monzó A, García-Gimeno T, Rubio JM, Montañana V, Duque C. Role of LH administration during the follicular phase in women with risk of low response in ovarian stimulation with FSH and cetrorelix for IVF [Papel de la administracion de LH en el curso de la fase folicular en mujeres con riesgo de pobre respuesta en ciclos de estimulacion con FSH y cetrorelix para FIV]. Revista Iberoamericana de Fertilidad y Reproduccion Humana 2006;23(5):281-90. 2976944
15. Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogeneous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproductive techniques. Fertility and Sterility 2004;82(6):1521-6. 2976946
16. Ferraretti AP, Gianaroli L, Motrenko T, Feliciani E, Tabanelli C, Magli MC. LH pretreatment as a novel strategy for poor responders. BioMed Research International 2014 Aug 12 [Epub ahead of print]. [http://dx.doi.org/10.1155/2014/926172]2976948
17. Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Human Reproduction 2005;20(5):1200-6. 2976950
18. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reproductive Biomedine 2004;8(6):635-43. 2976952
19. König TE, van der Houwen LE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WK, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Human Reproduction 2013;28(10):2804-12. 2976954
20. Kovacs P, Kovats T, Kaali SG. Results with early follicular phase recombinant luteinizing hormone supplementation during stimulation for in vitro fertilization. Fertility and Sterility 2010;93(2):475-9. 2976956
21. Levi-Setti PE, Cavagna M, Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of rFSH alone and in combination with rLH. European Journal of Obstetrics and Gynecology and Reproductive Biology 2006;126:212-16. 2976958
22. Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertility and Sterility 2005;83(2):309-15. 2976960
23. Lisi F, Caserta D, Montanino M, Berlinghieri V, Bielli W, Carfagna P, et al. Recombinant luteinizing hormone priming in multiple follicular stimulation for in-vitro fertilization downregulated patients. Gynecological Endocrinology 2012;28(9):674-7. [DOI: 10.3109/09513590.2011.652716]2976962
24. Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive Biomedicine Online 2003;8(2):175-82. 2976964
25. Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study. Reproductive Biomedicine Online 2009;19(6):879-87. 2976966
26. Mohseni F, Dehgani Firouzabadi R, Yari N, Etebary S. Results of adding recombinant LH in normoresponder patients for assisted reproductive technology treatment: a prospective randomized control trial. International Journal of Fertility and Sterility 2013;7:112. 5656471
27. Musters AM, van Wely M, Mastenbroek S, Kaaijk EM, Repping S, van der Veen F, et al. The effect of recombinant LH on embryo quality: a randomized controlled trial in women with poor ovarian reserve. Human Reproduction 2012;27(1):244-50. 2976968
28. Nazzaro A, Salemo A. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol improves implantation and pregnancy rates. Fertility and Sterility 2012;98(3):S280. 2976970
29. Nyboe Andersen A, Humaidan P, Fried G, Hausken J, Antila L, Bangsbøll S, et al. Nordic LH study group. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Human Reproduction 2008;23(2):427-34. 2976972
30. Pezzuto A, Ferrari B, Coppola F, Nardelli GB. LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecological Endocrinology 2010;26(2):118-24. 2976974
31. Razi MH, Mohseni F, Dehghani Firouzabadi R, Janati S, Yari N, Etebary S. Results from adding recombinant LH for assisted reproductive technology treatment: A randomized control trial. Iranian Journal of Reproductive Medicine 2014;12(2):111-6. 2976976
32. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertility and Sterility 2007;87(3):542-6. 2976978
33. Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Human Reproduction 2006;21(1):90-4. 2976980
34. Van Der Houwen L, Konig TE, Overbeek A, Hendriks ML, Beemsterboer SN, Kuchenbecker WK, et al. The influence of LH substitution for GnRH antagonist blocked endogenous LH in older IVF patients. Human Reproduction 2011; Vol. 26:i314-5. 2976982
35. Vuong TNL, Phung HT, Ho MT. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial. Human Reproduction 2015;30(5):1188-95. 2976984
36. Younis JS, Izhaki I, Ben-Ami M. The effect of LH supplementation following GNRH antagonist administration in advanced reproductive ageing women undergoing IVF-ET: A prospective randomized controlled study. Fertility and Sterility 2014;102(3):e23. 2976986
37. Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertility and Sterility 2004;82(2):343. 2976988
38. Barberi M, Ermini B, Morelli MB, Ermini M, Cecconi S, Canipari R. Follicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: Effects of recombinant LH administration. Journal of Assisted Reproduction and Genetics 2012;29(12):1381-91. 2976990
39. Baruffi RLR, Mauri AL, Petersen CG, Felipe V, Martins AMC, et al. The use of recombinant luteinizing hormone in addition to recombinant follicle-stimulating hormone in ovarian stimulation with the GnRH-antagonist protocol. Jornal Brasileiro de Reproducao Assistida 2006;10(4):9-16. 2976992
40. Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Human Reproduction 2004;19(9):1979-84. 2976994
41. Durnerin CI, Erb K, Fleming R, Hillier H, Hillier SG, Howles CM, et al. Luveris Pretreatment Group. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Human Reproduction 2008;23(2):421-6. 2976996
42. De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotropic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clinical Endocrinology 2004;60:637-43. 2976998
43. De Placido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertility and Sterility 2006;85(1):247-50. 2977000
44. Drakakis P, Loutradis D, Kallianidis K, Liapi A, Milingos S, Makrigiannakis A, et al. Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2005;121(1):77-80. 2977002
45. Fei Yang D, Jia Yin L. Different LH add-back and luteal phase supplement influence clinical outcome in GnRH antagonist protocol-a prospective RCT study in fresh and frozen transfer cycles. Fertility and Sterility 2013;100(3):S270. 2977004
46. Fermin A, Crisol L, Exposito A, Prieto B, Mendoza R, Matorras R. Influence of the fsh/lh ratio in ovarian stimulation in ivf results in women aged over 35 years: a randomized study. Human Reproduction 2013;28:i311-56. 2977006
47. Garcia-Velasco J, Coelingh Bennink HJ, Epifanio R, Escudero E, Pellicer A, Simón C. High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist. Reproductive Biomedicine Online 2007;15(3):280-7. 5656472
48. Gomez-Palomares JL, Acevedo-Martin B, Andres L, Ricciarelli E, Hernandez ER. LH improves early follicular recruitment in women over 38 years old. Reproductive BioMedicine Online 2005;11(4):409-14. 2977010
49. Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A, Recombinant LH Study Group. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Human Reproduction 2005;20(3):629-35. 2977012
50. Lahoud R, Foley J, Ryan J, Costello M, Quinn F, Illingworth P. Recombinant LH supplementation in patients with a relative reduction in lh levels during IVF/ICSI cycles: A prospective randomised controlled trial. Human Reproduction 2010;25(6):i90 (Abstract no. O-227). 2977014
51. Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG. Use of recombinant follicle-stimulating hormone (Gonal F) and recombinant luteinizing hormone (Luveris) for multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization. Fertility and Sterility 2003;79(4):1037-8. 2977020
52. Motta ELA, Maia V, Massaguer A, Fassolas G, Rocca T, Rossi LM, et al. Administration of either recombinant LH or increasing dose of recombinant FSH in late follicular phase of patients with suboptimal response. Abstracts of the 22nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2006 June 18-21; Prague. 2006:O-141, i55. 2977022
53. Papanikolaou E, Werpoest W, Fatemi H, Polyzos N, Humaidan P, Tarlatzis B, et al. Recombinant LH as luteal supplementation method after agonist triggering in IVF. A proof of concept study. 26th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2010 June 14-17; Lisbon. 2010:i167-8. 2977024
54. Sauer MV, Thornton MH 2nd, Schoolcraft W, Frishman GN. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reproductive Biomedicine Online 2004;9(5):487-93. 2977026
55. Sills ES, Levy DP, Moomjy M, McGee M, Rosenwaks Z. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Human Reproduction 1999;14(9):2230-5. 2977028
56. Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Human Reproduction 2002;17(12):3129-37. 2977030
57. Toporcerová S, Hredzák R, Ostró A, Zdilová V, Adam J, Potoceková D. Influence of serum levels of luteinizing hormone during controlled ovarian hyperstimulation on the results of IVF cycle [Vplyv exogénnej suplementácie luteinizacného hormónu pocas kontrolovaney ovariálnej hyperstimulácie na výsledky cyklu IVF]. Ceska Gynekologie 2005;70(4):247-53. 2977032
58. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
59. Broekmans F, Bernardus R, Berkhout G, Schoenmaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of LHRH agonist in a depot formulation: decapeptyl CR. Gynecoligal Endocrinology 1992;6:153-61.
60. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction 2011;26(7):1616-24.
61. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 12 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
62. Higgins JP, Tompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
63. Higgins JP, Green S, editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. [www.cochrane-handbook.org.]
64. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, et al. The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertility and Sterility 2012;97(5):1108-14.
65. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ 2009;339:2535.
66. Placido G, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotropic young women characterized by a poor initial response to recombinant FSH. Human Reproduction 2001;16:1875-9.
67. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
68. Short RV. Steroids in the follicular fluid and the corpus luteum of the mare. A 'two-cell type' theory of ovarian steroid synthesis. Journal of Endocrinology 1962;24:59-63.
69. Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Human Reproduction 1988;3(5):585-90.
70. Te Velde ER, Eijkemans R, Habbema HD. Variation in couple fecundity and time to pregnancy, an essential concept in human reproduction. Lancet 2000;355(9219):1928-9.
71. Vail A, Gardener E. Common statistical errors in the design and analysis of subfertility trials. Human Reproduction 2003;18:1000-4.
72. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD005354.pub2]
73. Xiong Y, Bu Z, Dai W, Zhang M, Bao X, Sun Y. Recombinant luteinizing hormone supplementation in women undergoing in vitro fertilization/ intracytoplasmic sperm injection with gonadotropin releasing hormone antagonist protocol: a systematic review and meta-analysis. Reproductive Biology and Endocrinology 2014;12:109.
74. Mochtar MMH, van Wely M, van der Veen F. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD005070]
75. Mochtar MH, Van der Veen F, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005070.pub2]